Vanda Pharmaceuticals Inc. has recently seen a notable change in its shareholder composition. State Street Corporation, a prominent financial institution, has disclosed its beneficial ownership of 5% of Vanda's common stock. This announcement was made through a Schedule 13G filing on November 10, 2026, and marks a significant event for the company.
Vanda Pharmaceuticals, traded on the Nasdaq under the ticker VNDA, operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company is headquartered in Washington, D.C., and focuses on developing innovative treatments for various medical conditions. The recent filing is part of a series of disclosures, with the most recent prior filing occurring just days earlier on November 5, 2026.
The Schedule 13G filing indicates that State Street Corporation holds a total of 3,010,531 shares of Vanda Pharmaceuticals, with shared voting power over 2,938,155 shares. This ownership stake highlights State Street's strategic interest in Vanda, reflecting confidence in the company’s potential within the competitive pharmaceutical industry.
This development could impact various stakeholders, including Vanda's management, existing shareholders, and potential investors. The increased ownership by a well-known financial institution like State Street may enhance Vanda's visibility in the market, potentially attracting further institutional investment.
As for what’s next, the filing does not specify any upcoming events or actions related to this ownership change. However, the attention from State Street could lead to increased scrutiny of Vanda's operations and future strategies.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




